Objective It is important to identify the best initial work-up in patients with uninvestigated dyspepsia because of its epidemiological and economical relevance. The objective of the study was to assess systematically the effectiveness and cost-effectiveness of invasive and non-invasive strategies for the management of dyspepsia.
Introduction
Dyspepsia is a common disorder, with reported prevalences ranging from 13 to 40% [1] . An international working party defined dyspepsia as 'upper abdominal or retrosternal pain, discomfort, heartburn, nausea, vomiting, or other symptoms considered being referable to the proximal alimentary tract' [2] . This is a broad definition that has been adopted by most studies. However, one important aspect is to exclude from dyspepsia patients with isolated heartburn or regurgitation that should be considered as having gastro-esophageal reflux disease [3] .
The impact of dyspepsia in terms of cost is also considerable. Drugs for dyspepsia represent a large percentage of the total cost of drugs in many healthcare systems, and the number of visits to primary care practitioners, investigation costs, especially endoscopies and testing for Helicobacter pylori, are increasing every year [4] .
Because of its importance in terms of prevalence and costs, this is a field of abundant research, both epidemiological and economic. Many studies have tried to address the issue of identifying the best initial work-up in patients with uninvestigated dyspepsia. In the past two decades two different approaches have mainly been proposed: (i) non-invasive strategies: empirical treatment with antisecretory drugs, or eradication treatment either empirical or based on the results of an H. pylori test (test and treat); and (ii) invasive strategies: initial endoscopy to all patients, or after selecting the best-suited candidates either by scoring models based on dyspeptic symptoms and patients' characteristics (score and scope), or in the light of the results of an H. pylori test (test and scope). some studies have claimed low effectiveness [6] and low levels of satisfaction among patients submitted to this strategy [7] , whereas others have claimed cost-effectiveness [8, 9] . The non-invasive test and treat strategy has been shown to be effective [10] and cost-effective [11] [12] [13] [14] in different studies, but there are many concerns about it, mainly the problem of increasing bacterial resistance [15] , and the low benefits, if any, of eradicating H. pylori in non-ulcer dyspepsia [16] . Although eradication treatment in non-ulcer dyspepsia has been shown to be cost-effective under certain conditions [17] , it is necessary to avoid unnecessary eradication, and to point out that deleterious rebound hypersecretion can appear in some patients after eradication treatment [18] . Moreover, recent data have again supported the use of empirical treatment with proton pump inhibitors for the initial management of dyspepsia [19] .
With regard to invasive strategies, gastroscopy is the gold standard investigation for dyspepsia [20] , and can reliably distinguish between patients with organic causes of dyspepsia such as peptic ulcer disease, reflux oesophagitis, or cancer, and patients with no underlying cause that are then labelled as functional dyspeptic individuals. Endoscopy can be normal in up to 60% of patients with dyspepsia, and a strategy based on initial endoscopy increases the workload for endoscopies without savings in medications or later visits according to some authors, but with benefits according to others [21] . If the cost of endoscopy is low, it could be a cost-effective alternative for the treatment of dyspeptic patients older than 45-50 years, because a precise diagnosis and an accurate treatment could give rise to a great reduction in dyspeptic symptoms [22] . The test and scope strategy has not been shown to be cost-effective [23] because it increases the number of endoscopies over usual practice in primary care, perhaps because of the low accuracy of the H. pylori rapid test used in primary care settings. Scoring systems aimed at selecting patients suitable for endoscopy, based on clinical symptoms and patients' characteristics, have shown higher predictive accuracy for the diagnosis of organic disease than H. pylori testing in environments with a high prevalence of infection [24] . Varying results have been reported, with sensitivities for the detection of major pathology from 86 to 97%, and savings in endoscopic workload varying between 23 and 33% [25, 26] .
Apart from all this information, no study has systematically compared the performance of all these strategies. The objective of this study was to assess the effectiveness and cost-effectiveness of several invasive and noninvasive strategies for the management of dyspepsia, i.e. prompt endoscopy, score and scope, test and scope, test and treat, and empirical antisecretory treatment. The results obtained in the present study would help to make recommendations about the optimal management strategy of dyspepsia from a cost-effectiveness point of view.
Methods
A decision analysis was performed to compare the effectiveness and cost-effectiveness of initial endoscopy, score and scope, test and scope, test and treat, and empirical antisecretory therapy for the management of dyspepsia. Figure 1 shows the decision tree used to perform the cost-effectiveness analysis (the complete tree is available from the authors upon request). The decision model considers patients that consult at primary care with uncomplicated dyspepsia, excluding patients with clinical suspicion of isolated reflux disease and patients with alarm clinical symptoms suggestive of malignant disease. At the first decision node, the primary care practitioner should decide between five different management strategies:
Endoscopy
The patient is referred for endoscopy. If the results of the endoscopy show a gastric ulcer or extensive erosive gastritis, a biopsy with histological examination is performed. If the results of the endoscopy show duodenal ulcer or erosive duodenitis, a rapid urease test is performed over an antral tissue sample. For positive results, an eradication treatment is prescribed (omeprazole, clarithromycin and amoxicillin for one week); for negative results, an antisecretory treatment is prescribed (omeprazole for 2 months). For oesophagitis and non-ulcer dyspepsia, normal endoscopy or minor lesions (less than five gastric erosions), an antisecretory treatment is also prescribed (omeprazole for 2 months). If the diagnosis is gastric cancer the patient is referred for surgical evaluation.
Score and scope
A previously locally validated scoring system [24] is performed on the patient. If the score shows a value equal to or greater than 7, the patient is at high risk of organic disease, and an endoscopy is performed, acting as previously stated. In the absence of alarm symptoms or a score value lower than 7, an antisecretory treatment is given to the patient (omeprazole for 2 months).
Test and scope
During the initial visit, a urea breath test is performed. If the result shows positive for H. pylori infection, the patient is referred for endoscopy. From now on, the patient goes through the same steps as in the endoscopy strategy. If the result of the breath test is negative, the primary care practitioner prescribes an antisecretory treatment (omeprazole for 2 months). H. pylori infection, an eradication treatment is prescribed (again omeprazole, clarithromycin and amoxicillin for one week). If the result is negative, an antisecretory treatment is prescribed (omeprazole for 2 months).
Empirical antisecretory treatment
During the initial visit, an antisecretory treatment is prescribed (omeprazole for 2 months) without performing any invasive or non-invasive diagnostic test.
Therapeutic effectiveness was measured as the rate of asymptomatic patients one year after the end of the treatment. The diagnostic accuracy values of the diagnostic tests considered in this study and their corresponding data sources, as well as the effectiveness data of the two drug treatments considered are listed in Table 1 [12, 13, 24, . Data on the prevalence of different diagnoses of dyspepsia in primary care populations, and rates of H. pylori infection are based on available scientific evidence, and on local data from a county hospital with primary care offices, located in an area of southern Europe (Hospital de Viladecans, Barcelona, Spain), which serves a population of 145 000 inhabitants. We also included local prevalence data and rates of infection from patients older and younger than 45 years coming from our sample. Values and references are listed in Table 1 .
As the perspective of analysis used was that of the public healthcare payer, only direct costs were included in the analysis, which corresponded to the cost of visits to a primary care practitioner, the cost of diagnostic tests, and the cost of drug treatments. In the endoscopy strategy (and all the strategies including endoscopy), one clinical visit to a primary care practitioner, an endoscopy, and a second visit to the primary care practitioner to check the endoscopic results and prescribe treatment were included. In the score and scope strategy, only one visit was included, because at the first visit the score is performed and the treatment prescribed. In the case of performing an endoscopy, the costs are as previously described. In the test and scope and test and treat strategies, two visits were included, because two visits are necessary to perform a breath test and check the results. Once the results are known, the physician could prescribe the treatment during the second visit, or refer the patient for endoscopy if needed (again, as previously described). In the case of empirical treatment, only one visit to the primary care practitioner was included.
The cost of both diagnostic tests and medical visits were estimated through costs, looking them up in the accounting system of the Hospital de Viladecans for 2001. In the sensitivity analysis, however, we included a lower and an upper bound. The lower bound corresponded to cost data coming from the tariff system used to reimburse the activity of public hospitals in Catalonia, estimated from administrative data from the Catalan Health Service for 2001, actualized to 2003. The upper bound corresponded to schedule fees used to reimburse activity by private insurers for 1997, actualized to 2003. For gastric cancer we included an estimated cost of surgery, also coming from the accounting system of the same hospital. For the estimation of the cost of drug therapies an eradication therapy comprising clarithromycin (500 mg every 12 h, for one week), amoxicillin (1000 mg every 12 h, for one week), and omeprazole (20 mg every 12 h, for one week) was considered, as well as an antisecretory therapy comprising omeprazole (20 mg every 24 h, for 2 months). The reference list prices of these drugs were used as a measure of the cost of the different therapies in 2001. All costs were actualized and converted to 2003 Euros using a 3% inflation rate, and are shown in Table 1 .
The measure of the economic analysis, the incremental cost-effectiveness ratio, was cost per asymptomatic patient, valued in 2003 Euros. The incremental costeffectiveness ratio was calculated as the additional cost of each strategy over the previous least costly alternative, divided by its additional effectiveness; empirical treatment was used as the reference alternative to calculate incremental values. The time-horizon established was one year post-therapy, and no discount rate was used because costs and benefits occurred in a period shorter than one year. Different one-way and two-way sensitivity analyses were performed to test the robustness of both the model and the results obtained against variations in the baseline variables. The model was designed to be internally consistent, i.e. the prevalence of each condition is the same in each strategy; when performing sensitivity analyses, just one or two variables were varied at a time. Data analyses were performed using Microsoft Excel and Data 3.5 Windows software packages (see Fig. 2 ).
Results
Endoscopy was found to be the most effective strategy for the management of dyspepsia, followed by test and scope, test and treat, score and scope, and empirical treatment ( Table 2) . A total of 38.4% of the patients were asymptomatic within one year in the endoscopy group, followed by 35.5% in the test and scope group, 35 .3% in the test and treat group, 34.7% in the score and scope group, and 28.5% in the empirical treatment group.
According to the age of the patients, endoscopy was also found to be the most effective strategy, although there were some changes in the relative order of the rest of the strategies. In particular, for patients older than 45 years, 39.8% were asymptomatic in the endoscopy group after one year, 37.0% in the test and treat group, 36 .6% in the test and scope group, 35 .4% in the score and scope group, and 28.5% in the empirical treatment group. The sensitivity analyses showed variations in a few cases.
For low values of prevalence of duodenal ulcer, test and treat is the most effective strategy (35.3%), followed by score and scope (34.7%); for high values of prevalence of gastric ulcer, endoscopy is the most effective strategy (40.9%), but is followed by score and scope (37.2%). For low values of healing of functional dyspepsia with antisecretory and eradication drugs, test and treat is the most effective strategy, followed by endoscopy. Finally, for low values of prevalence of H. pylori in dyspepsia, endoscopy is the most effective strategy (38.4%), followed by score and scope (34.7%), test and scope (32.7%), test and treat (31.9%), and empirical treatment (28.5%) ( Table 2) .
With regard to efficiency results and looking to incremental cost-effectiveness ratios, score and scope was the most cost-effective alternative. Score and scope provided additional clinical benefits over empirical treatment for Although the absolute values of the incremental costeffectiveness ratios vary according to the age of the patients, the relative order of the strategies do not vary for patients younger and older than 45 years (Table 3) . Sensitivity analysis showed variations in a few cases. When using low prevalence values of duodenal ulcer, low values of healing of functional dyspepsia with antisecretory treatment, and high values of healing of functional dyspepsia with eradication treatment, score and scope was the most cost-effective alternative, followed in those cases by test and treat ( Table 3 ).
The results do not change when varying the prevalence of H. pylori in dyspepsia, score and scope being the most cost-effective strategy, followed by endoscopy. No twoway sensitivity analyses showed variations with respect to the base case results.
Discussion
The results of our analysis show that endoscopy was the most effective alternative, whereas score and scope was the most cost-effective strategy.
The score and scope strategy is the main novelty of this analysis. The strategy is based on the selection of candidates for endoscopy by using a predictive model constructed by our group [24] . This predictive model for organic dyspepsia is a simple diagnostic tool, based on clinical symptoms and patient characteristics. It has a global predictive accuracy of 79%, with a sensitivity of 74% and a specificity of 70%. The good predictive accuracy of this scoring model has recently been 
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Incremental cost-effectiveness of the strategies (base case analysis, and age variations). The slope of the line indicates incremental costeffectiveness. Strategies above and left are dominated (more expensive and/or less effective). evaluated prospectively, confirming a value of 75% for organic dyspepsia when applied by primary care doctors and of 82% when applied by gastroenterologists [51] . The higher discriminant power of the scoring system over the H. pylori test [24] can explain the higher efficiency of score-based strategies over H. pylori testing strategies. This scoring system has been shown to be very useful in the process of the referral of dyspeptic patients from primary care to endoscopy units [51, 67] , especially in cases of long waiting lists for endoscopy [68] .
Other studies have analysed the cost-effectiveness of different strategies in dyspepsia by using decision analyses with different results [19, [69] [70] [71] [72] . Most of them suggest that test and treat, or empirical antisecretory treatment [9, 23, 73] are more cost-effective than endoscopy, whereas others have shown that endoscopy is the most cost-effective approach [21, 22] .
One important aspect to consider in the approach to dyspepsia is gastric cancer. Although an initial endoscopy strategy would detect all tumours, and some cancers can be missed if prompt endoscopy is not performed, a decrease in gastric cancer survival is not clearly demonstrated if an endoscopy is delayed a couple of months [74] . The incidence of cases of gastric cancer are negligible in younger patients in our population [24] , and alarm symptoms are usually good predictors of the suspicion of gastric cancer [75] , which will be detectable with a score and scope strategy. Test and scope cannot detect all gastric cancers because a small percentage of tumours are H. pylori negative. Neither test and treat nor empirical treatment could detect any gastric cancer case, although in some contexts eradication treatment has proved to be useful in reducing the development of some cases [76] .
Several limitations should be pointed out in this analysis associated with the assumptions used, and in defining the baseline clinical-economic setting of care. First, local data come from an area of high prevalence of H. pylori infection (68-70%) [24, 77] and a prevalence of ulcer disease among dyspeptic patients of 27% [24] . The high rate of ulcer disease is probably due to the fact that local data were obtained in a study on the relationship of symptoms of dyspepsia with endoscopic diagnosis, in which the delay between inclusion and the performance of endoscopy was less than 10 days. Recent studies have shown that the rate of ulcers among dyspeptic patients is decreasing [78, 79] , and other authors believe that lower rates of peptic ulcer among dyspeptic patients only reflect ulcer disease healed during the waiting list period for endoscopy [78] . However, it is very important to point out that the decision analysis model was robust in the face of changes in the prevalence of some organic diseases, the prevalence of H. pylori, the accuracy of diagnostic tests, and the age of the patients, score and scope being the most efficient strategy, followed by endoscopy. In particular, results did not change for higher and lower values of the prevalence of H. pylori in dyspepsia, ensuring the generalizability of the results to contexts with a lower H. pylori prevalence.
Second, the temporal horizon considered in the analysis was one year post-therapy, according to the effectiveness measure used and the costs included in the analysis (i.e. the number of asymptomatic patients in each branch one year after the initial treatment). This fact is relevant because it does not allow the inclusion of alternative or complementary diagnostic procedures and therapies after the first year of treatment, neither does it take into consideration relapses or the worsening of diseases, H. pylori infection, or resistance to the eradication treatment used. We abstained from constructing a longer time horizon model, to avoid the problems that assumptions about disease recurrence and alternative treatments would impose. In case there was good quality scientific evidence on these variables, a longer time horizon should be used in order to include all the consequences of the therapies. In addition, recent studies about quality of life of dyspeptic patients suggest lower cost-effectiveness ratios for those strategies that emphasize early eradication [80] .
Third, because the analysis was carried out from the perspective of the public healthcare payer instead of the societal perspective, no indirect costs were included in the model. Productivity losses could be relevant in dyspepsia, a disease with high associated indirect costs as a result of the symptoms, tests, and medical visits [81] . However, one could say that productivity losses would be smaller in the case of score and scope, an alternative that involves the least number of medical visits, and the least delays in terms of, for example, waiting time for results of tests and invasive procedures.
Fourth and also related to costs, in the base case analysis we used costs obtained from the accounting system of the hospital. When using public tariffs in the sensitivity analysis, cost-effectiveness ratios are slightly higher, because tariffs are higher or lower than costs, depending on the procedure. Tariffs, as charges, do not usually reflect the real cost of procedures [82, 83] . Using higher estimations of costs, the reimbursement fees of private insurers, the model yielded higher cost-effectiveness ratios, but maintained the same relative order of the compared alternatives (Table 3 ). Therefore, one could say that the same results would be obtained in other healthcare contexts in which, for example, endoscopy costs are much higher [84] .
Finally, the decision analysis had implicitly adopted percentages of compliance with drug therapies and diagnostic test uptakes of 100%. The risks associated with the performance of any of the specific diagnostic tests were not considered in the analysis, nor were the adverse effects of antisecretory and eradication therapies, or endoscopy. Dyspeptic symptoms cause significant disutility that should be incorporated into future costeffectiveness analyses of management strategies [85] . In this sense, the inclusion of patient preferences regarding the different diagnostic tests may be an interesting research area, using the most recently published scientific evidence and applying cost-utility analysis. Although we are aware of the recommendations of the Panel on Cost-effectiveness Analysis about the use of QALYs [86] , we did not use them because of the absence of validated data on quality of life about dyspepsia in our context [87] .
In conclusion, the current analysis showed that a management strategy based on score and scope is the most cost-effective approach. According to these results, we would recommend stratifying patients by a score system, referring first to endoscopy patients at higher risk of organic dyspepsia. Further studies taking into account the limitations found in this study should be designed, both with regard to the quality of scientific evidence on effectiveness data, the validity of the assumptions of the baseline analysis, and the measured costs, considering always its applicability in primary care [87, 88] . In the meantime, the results of this study could be included in clinical practice guidelines, once validated in each particular setting, contributing to decrease the existing variations, and to higher standards of care.
